[Present status and problems in vitamin D and sevelamer therapy (discussion)].
Tahara
Hideki
H
Yumita
Shigeru
S
Ishida
Mari
M
Tsuruta
Yoshinari
Y
Cunningham
John
J
Fukagawa
Masafumi
M
Tominaga
Yoshihiro
Y
Tokumoto
Masanori
M
Onoda
Noritaka
N
D002118:Calcium / Q000378:metabolism; D004359:Drug Therapy, Combination; D000431:Ethanol / Q000008:administration & dosage; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D007011:Hypoparathyroidism / Q000378:metabolism / Q000628:therapy; D015552:Injections, Intralesional; D016105:Parathyroidectomy; D010758:Phosphorus / Q000378:metabolism; D011073:Polyamines / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D044169:Receptors, Calcium-Sensing / Q000819:agonists; D000069603:Sevelamer; D014807:Vitamin D / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives
D011073:Polyamines; D044169:Receptors, Calcium-Sensing; D014807:Vitamin D; D010758:Phosphorus; D000431:Ethanol; D000069603:Sevelamer; D002118:Calcium